The modern history of cholesterol-lowering drugs started in 1972 when Dr. Akira Endo identified an active compound (compactin) that inhibited cholesterol biosynthesis from the culture broth of blue–green mold (Penicillium citrinum Pen-51). Since 1987, statins have represented the milestone for the treatment of atherosclerotic cardiovascular disease. A new therapy for the treatment of hypercholesterolemia since the discovery of statins is ezetimibe, the first and only agent inhibiting intestinal cholesterol absorption. Ezetimibe was approved by the FDA in October 2002. A year later, the association between gain-of-function PCSK9 genetic mutations and hypercholesterolemia was reported, and this discovery opened a new era in lipid-lowering therapies. Monoclonal antibodies and small-interfering RNA approaches to reduce PCSK9 were developed and approved for clinical use in 2015 and 2022, respectively. Finally, the newly approved bempedoic acid, an oral adenosine triphosphate citrate lyase inhibitor that lowers LDL-C, is able to reduce major adverse cardiovascular events in both primary and secondary prevention. In the present narrative review, we summarize the pharmacological properties and the clinical efficacy of all these agents currently used for a tailored therapy of hypercholesterolemia in patients with atherosclerotic cardiovascular disease.

Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review / N. Ferri, M. Ruscica, S. Fazio, A. Corsini. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 13:4(2024), pp. 943.1-943.24. [10.3390/jcm13040943]

Low-Density Lipoprotein Cholesterol-Lowering Drugs: A Narrative Review

M. Ruscica
Secondo
;
A. Corsini
Ultimo
2024

Abstract

The modern history of cholesterol-lowering drugs started in 1972 when Dr. Akira Endo identified an active compound (compactin) that inhibited cholesterol biosynthesis from the culture broth of blue–green mold (Penicillium citrinum Pen-51). Since 1987, statins have represented the milestone for the treatment of atherosclerotic cardiovascular disease. A new therapy for the treatment of hypercholesterolemia since the discovery of statins is ezetimibe, the first and only agent inhibiting intestinal cholesterol absorption. Ezetimibe was approved by the FDA in October 2002. A year later, the association between gain-of-function PCSK9 genetic mutations and hypercholesterolemia was reported, and this discovery opened a new era in lipid-lowering therapies. Monoclonal antibodies and small-interfering RNA approaches to reduce PCSK9 were developed and approved for clinical use in 2015 and 2022, respectively. Finally, the newly approved bempedoic acid, an oral adenosine triphosphate citrate lyase inhibitor that lowers LDL-C, is able to reduce major adverse cardiovascular events in both primary and secondary prevention. In the present narrative review, we summarize the pharmacological properties and the clinical efficacy of all these agents currently used for a tailored therapy of hypercholesterolemia in patients with atherosclerotic cardiovascular disease.
LDL-cholesterol; PCSK9; statins; bempedoic acid; ezetimibe; inclisiran
Settore MED/04 - Patologia Generale
Settore BIO/14 - Farmacologia
   EXTRAcellular Vesicles to Unravel Heart Failure Molecular and Clinical Phenotypes (EXTRAHF)
   EXTRAHF
   MINISTERO DELL'UNIVERSITA' E DELLA RICERCA
   2022ZPS49L_002

   Pharmacological inhibition and genetic deletion of PCSK9: in vitro and in vivo studies on smooth muscle cell aortic calcification
   MINISTERO DELL'UNIVERSITA' E DELLA RICERCA
   2022ZW3M8H_001
2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
Nicola Ferri.pdf

accesso aperto

Descrizione: Review
Tipologia: Publisher's version/PDF
Dimensione 1.09 MB
Formato Adobe PDF
1.09 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1028528
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact